The burgeoning field of diabetes therapy has seen tremendous progress with the emergence of novel incretin mimetics like semaglutide and tirzepatide. These medications demonstrate promising results in managing blood sugar levels, altering the treatment paradigm for type 2 diabetes. However, their deployment on a global scale requires careful evalua